The University of Hawaii through support from the DAIDS Minority Infrastructure initiative (RFA 90-AI-04) has developed an adult AIDS Clinical Trials Unit (ACTU) in Honolulu on the island of Oahu for the study of therapy for HIV infection and associated opportunistic infections and malignancies in Asian/Pacific Islanders. Resources of the John A. Burns School of Medicine, the Research Centers in Minority Institutions (RCMI) Program, and the Hawaii State Department of Health are integrated to provide infrastructure for the Hawaii ACTU. The project will be directed by Dr. Margo Heath-Chiozzi who has five years of prior ACTG experience. Current procedures will be used for the conduct of clinical trials including data management, quality assurance monitoring, investigational drug management, and laboratory specimen processing. Immunologic and virologic laboratory tests will be conducted in ACTG-certified laboratories at the University of California, Los Angeles. The Hawaii ACTU plans to enroll approximately 80 patients per year in phase II/III antiretroviral studies, opportunistic infection treatment and prophylaxis studies, and Kaposi's sarcoma treatment studies. Outreach strategies will be specifically focused for statewide recruitment from Oahu and the Neighbor Islands of under-represented groups including Asian/Pacific Islanders, injection drug users, women and adolescents. The scientific capabilities of the Hawaii ACTU will be utilized to develop new protocols which examine the unique aspects of HIV-infected patients in Hawaii such as the use of antiretroviral agents in minority patients who have concurrent infections with Hepatitis B or HTLV-I. The professional development of minority investigators from Hawaii will be facilitated through participation on protocol teams and ACTG scientific and resource committees. The goal of this project is to support the adult Hawaii ACTU to participate in ACTG protocols which evaluate new therapies for HIV infection and the multiple sequelae of the immune dysfunction caused by HIV with targeted statewide recruitment of Hawaii's unique minority patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI034853-07
Application #
2856018
Study Section
Special Emphasis Panel (SRC (30))
Program Officer
Batzold, Frederick
Project Start
1996-01-01
Project End
1999-12-31
Budget Start
1999-01-01
Budget End
1999-12-31
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Hawaii
Department
Family Medicine
Type
Schools of Medicine
DUNS #
121911077
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9

Showing the most recent 10 out of 114 publications